Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cocrystal Pharma Inc (COCP)
NASDAQ:COCP
Holding COCP?
Track your performance easily
COCP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $3.10
Previous Close$1.75
Volume6.72K
Average Volume (3M)21.26K
Market Cap
$18.41M
Enterprise Value$1.44M
Total Cash (Recent Filing)$18.14M
Total Debt (Recent Filing)$1.78M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Nov 11, 2024EPS Estimate
-$0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.76
Shares Outstanding10,173,790
10 Day Avg. Volume12,546
30 Day Avg. Volume21,257
Standard Deviation0.34
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.79
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$8.50Price Target Upside369.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cocrystal Pharma News
PremiumCompany Announcements
Cocrystal Pharma Engages Investors at Upcoming Conferences
PremiumCompany Announcements
Cocrystal Pharma’s Promising Antiviral Candidate for Influenza ABulls Say, Bears Say
Bulls Say
Clinical Trial ResultsCDI-988 yields favorable Phase 1 results with no serious adverse events or treatment-emergent adverse events reported.
Drug Development ProgressCDI-988 has completed the single ascending dose stage of the Phase 1 trial for its oral protease inhibitor in development for norovirus and coronavirus, with safety and tolerability considered sufficient to continue to the next stage.
Vaccine EfficacyStudies of influenza drug CC-42344 have shown efficacy against the new avian influenza strain H5N1, making it an effective vaccine.
Bears Say
Equity DilutionFinancial results reported—lowering price target to account for projected equity dilution.
Financial PerformanceCocrystal Pharma reported a 2Q24 net loss of $0.53 per share, moderately wider than the forecast for a net loss of $0.43 per share.
Industry ImpactAvian influenza H5N1 has caused significant illness in commercial bird flocks since 2003.
---
Ownership Overview
88.80%
Insiders
3.32% Mutual Funds
2.68% Other Institutional Investors
5.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
COCP FAQ
What was Cocrystal Pharma Inc’s price range in the past 12 months?
Cocrystal Pharma Inc lowest stock price was $1.32 and its highest was $3.10 in the past 12 months.
What is Cocrystal Pharma Inc’s market cap?
Currently, no data Available
When is Cocrystal Pharma Inc’s upcoming earnings report date?
Cocrystal Pharma Inc’s upcoming earnings report date is Nov 11, 2024 which is in 53 days.
How were Cocrystal Pharma Inc’s earnings last quarter?
Cocrystal Pharma Inc released its earnings results on Aug 14, 2024. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.053.
Is Cocrystal Pharma Inc overvalued?
According to Wall Street analysts Cocrystal Pharma Inc’s price is currently Undervalued.
Does Cocrystal Pharma Inc pay dividends?
Cocrystal Pharma Inc does not currently pay dividends.
What is Cocrystal Pharma Inc’s EPS estimate?
Cocrystal Pharma Inc’s EPS estimate is -$0.57.
How many shares outstanding does Cocrystal Pharma Inc have?
Cocrystal Pharma Inc has 10,173,790 shares outstanding.
What happened to Cocrystal Pharma Inc’s price movement after its last earnings report?
Cocrystal Pharma Inc reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went down -10.526%.
Which hedge fund is a major shareholder of Cocrystal Pharma Inc?
Currently, no hedge funds are holding shares in COCP
---
Cocrystal Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (369.61% Upside)
$8.50 (369.61% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.79%
12-Months-Change
Fundamentals
Return on Equity
-68.86%
Trailing 12-Months
Asset Growth
-40.54%
Trailing 12-Months
Company Description
Cocrystal Pharma Inc
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded on January 2, 2014 and is headquartered in Bothell, WA.
---
COCP Stock 12 Month Forecast
Average Price Target
$8.50
▲(369.61% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Cyclacel Pharmaceuticals
―
Oragenics
―
SELLAS Life Sciences Group
―
Best Analysts Covering COCP
1 Year
1 Year Success Rate
1/19 ratings generated profit
1 Year Average Return
-42.27%
reiterated a buy rating last month
Copying Robert LeBoyer's trades and holding each position for 1 Year would result in 5.26% of your transactions generating a profit, with an average return of -42.27% per trade.
---